Form 4: Summit Therapeutics Co-CEO Exercises Warrants, Acquires Shares

Mahkam Zanganeh, Co-CEO of Summit Therapeutics, exercised warrants to purchase 315,681 shares of common stock at $1.58 per share.

Summary

• On October 3, 2024, Mahkam Zanganeh, Co-CEO of Summit Therapeutics, exercised warrants to purchase 315,681 shares of the company's common stock.
• The exercise price was $1.58 per share.
• The warrants were exercised by the Shaun Zanganeh Irrevocable Trust, with Mahkam Zanganeh as Trustee.
• Following the transaction, Zanganeh directly owns 31,000 shares and indirectly owns 10,199,776 shares through the Shaun Zanganeh Irrevocable Trust, 25,457,666 shares through the Mahkam Zanganeh Revocable Trust and 50,000 shares through an immediate family member.
• Zanganeh disclaims beneficial ownership of the indirectly held securities except to the extent of her pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a routine transaction disclosure. The exercise of warrants could be seen as a positive signal, but it's not definitively bullish.

Positives

• The Co-CEO's exercise of warrants could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade in their company's stock. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates